L'Oreal Expands Dermatological Skincare Line with Medik8 Acquisition

L'Oreal, the French cosmetics behemoth, is set to acquire British skincare brand Medik8, as announced by its owner, the UK-based private equity firm Inflexion, on Monday. While the financial details remain undisclosed, this strategic move aims at bolstering L'Oreal's offerings in the burgeoning dermatological skincare market.

Medik8 is known for its vitamin A-centric anti-ageing creams and serums. The collaboration with L'Oreal will not only enable Medik8 to solidify its presence in existing markets but also to expand on a global scale. Inflexion is set to retain a minority shareholding in Medik8 post-acquisition.

L'Oreal's dermatological beauty division, home to top brands like CeraVe and La Roche-Posay, has been the company's fastest-growing segment, with revenues hitting 7 billion euros last year. However, with growth slowing due to rising competition, L'Oreal is keen on acquisitions like Medik8 to revive its momentum.

(With inputs from agencies.)